Outcomes in all patients | n=29 830 | n=18 561 | | n=17 310 | n=17 310 | |
Collection of SABA ≥3 times in first year | 785 (2.6%) | 616 (3.3%) | <0.001 | 470 (2.7%) | 573 (3.3%) | 0.001 |
Collection of SABA ≥3 times any year | 2591 (8.7%) | 1765 (9.5%) | 0.002 | 1516 (8.8%) | 1622 (9.4%) | 0.047 |
Prescription of OCS in first year | 2697 (9.0%) | 1923 (10.4%) | <0.001 | 1579 (9.1%) | 1775 (10.3%) | <0.001 |
Prescription of OCS during follow-up | 4957 (16.6%) | 3651 (19.7%) | <0.001 | 2990 (17.3%) | 3405 (19.7%) | <0.001 |
Hospitalisation due to OLD | 153 (0.5%) | 114 (0.6%) | 0.14 | 102 (0.6%) | 100 (0.6%) | 0.89 |
Incident OLD | 2025 (6.8%) | 1296 (7.0%) | 0.41 | 1184 (6.8%) | 1197 (6.9%) | 0.78 |
Incident cancer (except skin cancer) | 1183 (4.0%) | 838 (4.5%) | 0.003 | 711 (4.1%) | 787 (4.5%) | 0.045 |
Incident lung cancer | 47 (0.16%) | 58 (0.31%) | <0.001 | 24 (0.14%) | 56 (0.32%) | <0.001 |
Mortality during follow-up | 712 (2.4%) | 490 (2.6%) | 0.082 | 406 (2.3%) | 441 (2.5%) | 0.22 |
Outcomes in patients with OLD | n=3640 | n=2492 | | n=2213 | n=2294 | |
Collection of SABA ≥3 times in first year | 668 (18.4%) | 552 (22.2%) | <0.001 | 403 (18.2%) | 514 (22.4%) | <0.001 |
Collection of SABA ≥3 times in a 1-year timespan | 1632 (44.8%) | 1165 (46.7%) | 0.14 | 988 (44.6%) | 1079 (47.0%) | 0.11 |
Prescription of OCS in first year | 858 (23.6%) | 654 (26.2%) | 0.017 | 513 (23.2%) | 597 (26.0%) | 0.027 |
Prescription of OCS | 1325 (36.4%) | 1037 (41.6%) | <0.001 | 815 (36.8%) | 957 (41.7%) | <0.001 |
Hospitalisation due to OLD | 122 (3.4%) | 93 (3.7%) | 0.43 | 79 (3.6%) | 80 (3.5%) | 0.88 |
Incident cancer (except skin cancer) | 174 (4.8%) | 120 (4.8%) | 0.95 | 108 (4.9%) | 107 (4.7%) | 0.73 |
Incident lung cancer | 13 (0.36%) | 13 (0.52%) | 0.33 | 9 (0.41%) | 13 (0.57%) | 0.44 |
Mortality during follow-up | 159 (4.4%) | 115 (4.6%) | 0.65 | 101 (4.6%) | 99 (4.3%) | 0.69 |